Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT04067180 |
| Other study ID # |
DNR: 2017/8 |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
November 12, 2019 |
| Est. completion date |
August 26, 2022 |
Study information
| Verified date |
April 2023 |
| Source |
Karolinska Institutet |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This study compares haplo-identical family donor stem cell transplantation (haplo SCT) to
matched unrelated donor transplantation (URD SCT) in adult patients with acute myeloid
leukemia (AML) with the hypothesis that haplo SCT is as good as URD SCT.
Background:
A haplo-identical family donor is a relative sharing 50% of the human leukocyte antigens
(HLA) of the patient. SCT with this type of donor is increasing, and a number of
retrospective studies have demonstrated its feasibility, but prospective randomized studies
are still lacking. Such studies are necessary to establish the benefits of haplo SCT. For the
≈70% of the patients that lack the 1st choice donor, an HLA-matched sibling, the 2nd choice
is an URD at most centers. However, if haplo-identical donors are as good as URDs, this could
change. Haplo-identical donors have several advantages. Almost all patients have at least one
available haplo-identical donor, while URDs can be difficult to find. It also eliminates the
need for time-consuming donor searches, and is considerably less costly.
The Study:
Patients can be included in the study if they have AML and require SCT, ≥18 years, DO NOT
have an HLA-matched sibling donor, and DO have potential haplo-identical family donors AND
URDs.
After enrollment in the study, the patients are assigned randomly to either haplo SCT or URD
SCT. The treatment surrounding the transplantation differs according to the donor type.
Patients receiving haplo-identical transplantation are treated with a specified chemotherapy
protocol before transplantation and a chemotherapy combined with immunosuppressive drugs
after the transplantation to prevent graft-vs. host disease (GVHD). The patients receiving
URD SCT will be treated according to the standard protocol at their center. Thus, haplo SCT
will be compared to what is currently used in patients without an HLA-identical sibling
today.
The primary endpoint of this study is graft-vs.-host disease- and relapse free survival two
years after study inclusion. This measurement takes into account the side effect that causes
the most long-term suffering, graft-vs-host disease, as well as leukemia relapse and thus
indicates to what extent the treated patients remain relapse-free and without significant
side effects. Secondary end points include relapse-free survival, frequencies of
graft-versus-host disease and of infections, and the patients will be followed in the study
for five years.
Description:
This is a randomized, intention-to-treat, open label, non-inferiority study performed in an
international multicenter setting comparing allogeneic stem cell transplantation (SCT) with
haplo-identical family donors (haplo SCT) to matched unrelated donor (URD) SCT in adult
patients with de novo or treatment related acute myeloid leukemia (AML). The primary study
objective is to compare GVHD and relapse free survival (GRFS) at 2 years post-randomization
in patients randomized to Haplo-SCT with patients randomized to URD-SCT.
The choice of hematopoietic stem cell donor, the humal leukocyte antigen (HLA) match, and the
type of graft used are factors of major importance for survival and the risk of complications
after SCT. The use of haplo-identical donors has shown very promising results and may result
in a paradigm shift in SCT. However, no prospective randomized studies comparing unrelated
donors, the standard choice today when no HLA-identical sibling is available, with
haplo-identical donors have been published. The purpose of this study is to evaluate in a
prospective and randomised fashion whether haplo-identical donor SCT could yield similar
results to SCT with unrelated donors in patients with AML.
HYPOTHESIS:
The graft-vs.-host disease- and relapse-free survival two years after randomization (2-year
GRFS) after haplo SCT is not inferior to 2-year GRFS after URD SCT with donors matched at 7/8
or 8/8 of the major HLA loci.
STUDY POPULATION
Adult patients with de novo or treatment-related acute myeloid leukemia with indication for
allogeneic stem cell transplantation (SCT). MDS-AML and significant extramedullary AML
disease is excluded to make the study population more homogeneous.
Main inclusion criteria: Adult patients (age ≥ 18 years) with de novo or treatment-related
AML, eligible and fit for SCT, with at least one potential haplo-identical related donor and
at least five potential HLA-A, -B, and -DRB1 antigen matched unrelated donors (URD)
identified prior to inclusion.
Main exclusion criteria: Patients with a suitable HLA-identical sibling donor, and patients
with less than five potential URDs, and/or without a potential haplo-identical related donor.
Sample size: The total target enrollment is 200 patients, 100 patients in each treatment arm.
STUDY PLAN
Randomization is performed when it has been determined that all inclusion criteria are
fulfilled and no exclusion criteria are met. Patients will be randomized at a ratio 1:1
between the treatment arms using the permuted block technique, stratified by center to reduce
geographic and recruitment location related bias.
CHOICE OF DONOR AND STEM CELL SOURCE Donors for Haplo-SCT are required to be healthy and
18-60 years of age. Siblings, children and parents are acceptable. The choice of donor is
based on the clinical experience and current standard procedure at each center, taking
factors such as ABO-match, presence of relevant HLA-antibodies in the recipient,
cytomegalovirus (CMV)-serology compatibility, female donor to male recipient, and donor age
into consideration. The presence of significant levels of HLA-antibodies against mismatched
HLA molecules of the donor renders that donor unsuitable for transplantation. The primary
stem cell source for Haplo-SCT in the study is bone marrow. The target dose is > 4 ×10(8)
total nucleated cells (TNC)/kg patient weight. Peripheral blood stem cell grafts can be used
without breaking study protocol, but is strongly discouraged in patients where bone marrow
harvest of the donor is possible. If PBSC is used for Haplo-SCT in this trial, the maximum
cell dose recommended is 5 ×10(6) CD34+ cells/kg patient weight.
The choice of URD is to be based on the standard donor selection algorithm and guidelines at
each participating center. The chosen URD need to be allele-matched for HLA-A, -B, and -DRB1.
For HLA-C, one allele or antigen mismatch is allowed. If the HLA-match between the recipient
and several URDs are acceptable, other donor SCT-factors (e.g. CMV-status, ABO-compatibility,
sex-match, previous pregnancies, age, weight, etc.) should be taken into consideration before
the final donor choice. The choice of stem cell source (BM or PBSC) and CD34+ cell dose and
total nucleated cell dose should be according to current institutional practice.
For patients randomized to either treatment arm where no suitable donor can be identified,
cross over to the other arm is permitted.
TREATMENT PLAN
CONDITIONING:
Patients randomized to haplo SCT will be treated according to the Genoa protocol. This
protocol is based on the administration of thiotepa 5 mg/kg/day for two days (day -6, -5),
busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive
days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan
at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2). For elderly patients (> 60
years), or patients in poor clinical condition, the dose of busulfan may be reduced (e.g. by
reducing the number of treatment days, usually to 2 days for patients > 60 years old). GVHD
prophylaxis for Haplo-SCT is cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A (CyA) and
mycophenolate mofetil (MMF).
Patients randomized to URD SCT are treated according to the conditioning protocols used in
standard practice, with a recommendation to use the conditioning regimens "Flu+Bu"
(fludarabine + busulfan, with a total dose of Bu of 8-16 mg/kg body weight orally, or
6,4-12,8 mg/kg i.v.) or "Bu+Cy" (busulfan + cyclophosphamide, with a dose of Cy not exceeding
50 mg/kg x 2). If possible, all participating centers are recommended to use one
myeloablative conditioning (MAC) protocol and one reduced intensity (RIC) protocol for
included URD-SCT study patients throughout the study. In the majority of the participating
centers, protocols including anti-thymocyte globulin (ATG) is administered. The choice of
GVHD prophylaxis for the URD-SCT arm is to be performed according to the same principle as
the conditioning regimen, i. e. the standard practice at the center should be applied.
IMMUNOSUPPRESSION:
The dose of CyA should be targeted and adjusted to a set serum concentration as per center
preference. As a general guide, patients that have undergone Haplo-SCT could be kept at a
slightly lower concentration compared to patients that have undergone URD-SCT. The guiding
dosage principle is that CyA is given i.v. or p.o. at full dose from day 0 in the Haplo-SCT
arm (from day -1 in the URD-SCT patients receiving CyA) to day +90 approximately, then to be
tapered in the absence of GvHD and discontinued at 5-6 months after SCT or earlier if
clinically indicated. Tacrolimus may replace CyA if the patient does not tolerate CyA.
In haplo SCT patients, MMF is given at 15 mg/kg x 2 orally, starting at day +1 post SCT. It
is recommended to use MMF orally, but i.v. MMF is accepted. Dose adjustment is necessary in
patients suffering from severely impaired kidney or liver function. MMF is discontinued day
+28. In case MMF is used in URD-SCT patients, this is to be done according to the standard
protocols of the transplant center concerned.
Other relevant GVHD prophylaxis strategies for URD-SCT are also permitted.
SUPPORTIVE CARE
Supportive care is to be performed according to standard procedure at each participating
center.
FOLLOW UP
Patients will be followed for GRFS, survival, relapse, and other listed end-points at
designated time points. The primary endpoint will be reached when the last included patient
has a follow-up time of 2 years. The study will be terminated when the last included patient
has a follow-up time of five years. Data collection is continued even if the assigned therapy
was not carried out, since the main study analyses are intention-to-treat analyses.
Per-protocol analyses will be performed as well.
STUDY-SPECIFIC SAMPLES
Study samples from peripheral blood:
Study samples from peripheral blood are requested at the visit for randomization, at the day
of SCT-graft infusion (day 0), and at follow-up visits after 1, 3, 6, 12 and 24 months
post-SCT. At all of these time-points,
Study samples from bone marrow:
Study samples from bone marrow aspiration material are requested at the follow-up visits
after 2-3, 6, 12 and 24 months post-SCT (see Appendix IV for reference). At all of these
time-points,
STUDY MANAGEMENT
Source data and data management Data will be collected continuously and entered into the
study specific electronic case report form (eCRF). Study-related documents will be retained
for at least 25 years.
Quality control and monitoring The study will be monitored regularly according to good
clinical practice (GCP) and local regulations to ensure accurate, complete and reliable data.
All information reported in the eCRF will also be documented in the patient's file unless
otherwise specified.
Patient information and consent Before inclusion patients will receive verbal and written
information including a description of the trial, its purpose, the risks and the procedures
involved. Written informed consent must be obtained from all patients before enrollment in
the study.
Adverse Event (AE) Reporting Reported in the eCRF according to CTCAE version 4.03.
Serious Adverse Event (SAE) reporting For the purpose of this study, SAEs that are regarded
as expected events considering the given treatment (i.e. allogeneic hematopoietic stem cell
transplantation) and underlying disease, need not be reported as SAEs. However, all deaths
and unexpected significant SAEs are to be reported.
Study Safety Board A Study Safety Board (SSB) will perform safety analyses during the study.
This is a study independent data-monitoring committee that is established by the Sponsor to
assess at intervals the progress of the clinical trial, the safety data, and the critical
endpoints of the trial. The SSB will consist of three members, with at least one independent
statistician and two internationally renowned clinical hematologists.
The SSB will receive at least the following reports from the trial statistician for review:
- Interim analysis reports when 50% of the patients have been included, and when 100% of
the patients have been included in the trial.
- Annual safety data listing the incidence of (serious) adverse events.
- Annual progress data listing the number of enrolled patients and the status of data
collection.
Study termination and stopping rules
Regular study termination The study will be terminated when the last included surviving
patient has a follow-up of five years in the trial.
Stopping rules Termination of the study will be considered if, at the first interim analysis,
the rate of non-relapse mortality (NRM) ≥ 40% at 200 days after SCT, and/or the rate of acute
GVHD grades III-IV ≥ 20% in evaluable patients (with sufficient follow-up time or evaluation)
in the Haplo-SCT arm.
